ArticleJournal of translational medicine2026
TYRP1 defines a proliferative melanoma cell subpopulation, driving malignant progression and therapy resistance via the GPNMB-Notch1-SOX10/MITF axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor cell heterogeneity contributes to melanoma progression, therapeutic resistance, and clinical outcome variability. However, the identity and functional role of specific proliferative subpopulations remain incompletely understood. This study aims to characterize TYRP1-positive melanoma cells and elucidate their role in tumor proliferation, signaling regulation, and treatment response.
methodsWe analyzed single-cell RNA sequencing (scRNA-seq) data from primary and metastatic melanoma samples to identify transcriptionally distinct tumor cell subtypes. Functional validation of TYRP1-positive cells was performed using patient-derived organoids, TYRP1-overexpressing melanoma cell lines (A375, SK-MEL-28), and xenograft mouse models. The downstream molecular mechanisms were investigated through gene expression profiling, siRNA-mediated knockdown, recombinant protein treatment, and pathway inhibition assays. Therapeutic responses were assessed using dabrafenib and pembrolizumab treatments.
resultsTYRP1 marked a transcriptionally distinct melanoma subpopulation associated with poor patient survival. TYRP1-high organoids and cell lines exhibited significantly enhanced proliferation in vitro and accelerated tumor growth in vivo, without increased metastatic capacity. Mechanistically, TYRP1 induced expression of GPNMB, which activated Notch1 signaling and subsequently upregulated SOX10 and MITF. These transcription factors formed a positive feedback loop with TYRP1 that maintained the proliferative phenotype. GPNMB or Notch1 inhibition disrupted this loop and suppressed tumor growth. Importantly, TYRP1-overexpressing tumors demonstrated resistance to immune checkpoint blockade but increased sensitivity to dabrafenib, suggesting distinct therapeutic vulnerabilities.
conclusionsOur findings identify TYRP1 as a marker of a highly proliferative melanoma subpopulation that promotes tumor progression through the GPNMB-Notch1-SOX10/MITF axis. The TYRP1-SOX10-MITF feedback loop represents a key driver of melanoma proliferation and a potential biomarker for stratifying therapeutic response, offering a novel avenue for precision treatment in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.